Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20314201 | 0.92 | PRMT5 (0.42) | MEN1KMT2AMAPK1HTTSMN1; SMN2 | |
| SCHEMBL20314193 | 0.89 | MEN1 (0.49) | MEN1KMT2AMAPK1HTTSMN1; SMN2 | |
| SCHEMBL20324511 | 0.88 | ANO1 (0.43) | MEN1KMT2AMAPK1HTTSMN1; SMN2 | |
| SCHEMBL20314092 | 0.88 | MEN1 (0.43) | MEN1KMT2AMAPK1HTTSMN1; SMN2 | |
| SCHEMBL20314177 | 0.87 | BCHE (0.47) | MEN1KMT2AMAPK1BCHEALDH1A1 | |
| SCHEMBL20314147 | 0.85 | SLC6A4 (0.45) | MEN1KMT2AMAPK1HTTSMN1; SMN2 | |
| SCHEMBL20314089 | 0.85 | SMN1; SMN2 (0.59) | MEN1KMT2AMAPK1HTTSMN1; SMN2 | |
| SCHEMBL20314101 | 0.82 | BCHE (0.49) | MEN1KMT2AMAPK1HTTSMN1; SMN2 | |
| SCHEMBL20314206 | 0.82 | MEN1 (0.46) | MEN1KMT2AMAPK1HTTSMN1; SMN2 | |
| SCHEMBL20314110 | 0.81 | CXCR4 (0.45) | MEN1KMT2AMAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2020-04-16 | — | — | US | disclosed |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | Basilea Pharmaceutica International AG (CH) | 2019-11-05 | — | — | US | disclosed |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-06-28 | — | — | US | disclosed |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | MEN1 3487/4885KMT2A 4516/4885MAPK1 636/4885 |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | ABCB11, ABCC1, ABCC3 | MEN1 3443/4885KMT2A 4520/4885MAPK1 641/4885 |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | MEN1 3443/4885KMT2A 4520/4885MAPK1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.